Welcome
STATE-OF-THE-ART SOLUTION FOR DETECTING ALZHEIMER’S DISEASE EARLY
System for diagnosing Alzheimer’s even before significant cognitive impairment, using rapid diagnostic test & smart phone app
About Heuristyx Neural Diagnostics
Company's Mission
Company's Mission
Company's Mission
Heuristyx Neural Diagnostics' mission is to provide an accurate, convenient diagnostic test for Alzheimer’s disease which includes a mobile device app that displays the test result as well as FDA-approved treatments and open clinical trials of potential treatments on patient’s smart phone screen periodically. Patients can express their in
Heuristyx Neural Diagnostics' mission is to provide an accurate, convenient diagnostic test for Alzheimer’s disease which includes a mobile device app that displays the test result as well as FDA-approved treatments and open clinical trials of potential treatments on patient’s smart phone screen periodically. Patients can express their interest in a particular Alzheimer’s drug trial by simply selecting an onscreen button on their smart phone. Automatic notification of open clinical trials of new drugs will expedite the trials’ recruiting phase, bringing new Alzheimer’s drugs to market sooner.
Company's Vision
Company's Mission
Company's Mission
As new Alzheimer’s biomarkers are discovered by medical researchers, supervised machine learning is employed to periodically update the diagnostic classification model in the smart phone software app. The ultimate goal is to rely exclusively on non-invasive biomarker testing, such as saliva testing, for accurate diagnosis anywhere. By eli
As new Alzheimer’s biomarkers are discovered by medical researchers, supervised machine learning is employed to periodically update the diagnostic classification model in the smart phone software app. The ultimate goal is to rely exclusively on non-invasive biomarker testing, such as saliva testing, for accurate diagnosis anywhere. By eliminating invasive biomarker tests, more people will be motivated to get tested before significant memory issues occur, when Alzheimer’s drugs are most effective.
Company's Status
Heuristyx Neural Diagnostics is currently in the seed funding stage, and the Alzheimer’s diagnostic technology has been patented in 2024. This funding will enable completion of the diagnostic classification model within the Alzheimer’s Alert application software, using supervised machine learning algorithm to optimize this classification model’s sensitivity and specificity based on selected Alzheimer’s biomarker test results. Additional funding may come through a Small Business Innovative Research (SBIR) grant up to $1,972,828, a Commercialization Readiness Pilot (CRP) grant up to $3,945,657, and the Clinical Trial Planning Grant Program (R34) up to $450,000, all sponsored by NIH.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.